| 1.865 -0.095 (-4.85%) | 05-04 12:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.65 | 1-year : | 7.99 |
| Resists | First : | 4.84 | Second : | 6.84 |
| Pivot price | 4.06  |
|||
| Supports | First : | 1.61 | Second : | 1.33 |
| MAs | MA(5) : | 1.82 |
MA(20) : | 4.37 |
| MA(100) : | 5.38 |
MA(250) : | 4.15 |
|
| MACD | MACD : | -1 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 4.9 |
D(3) : | 3.8 |
| RSI | RSI(14): 23.9 |
|||
| 52-week | High : | 6.88 | Low : | 1.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CMPX ] has closed above bottom band by 20.8%. Bollinger Bands are 508% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.01 - 2.02 | 2.02 - 2.03 |
| Low: | 1.73 - 1.74 | 1.74 - 1.75 |
| Close: | 1.95 - 1.96 | 1.96 - 1.97 |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Fri, 01 May 2026
CMPX Stock Plunges As Traders Weigh Cancer Trial Fallout - StocksToTrade
Fri, 01 May 2026
CMPX Forecast, Price Target & Analyst Ratings | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Thu, 30 Apr 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX - PR Newswire
Wed, 29 Apr 2026
Compass Therapeutics (CMPX) CAO receives 15,000-share equity grant - Stock Titan
Wed, 29 Apr 2026
CMPX Stock Sinks As Trial Failure Hammers Compass Therapeutics - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 180 (M) |
| Shares Float | 119 (M) |
| Held by Insiders | 12.4 (%) |
| Held by Institutions | 88.2 (%) |
| Shares Short | 26,070 (K) |
| Shares Short P.Month | 23,820 (K) |
| EPS | -0.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.3 % |
| Return on Equity (ttm) | -41.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -49 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -4.48 |
| PEG Ratio | 0 |
| Price to Book value | 1.7 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|